High Dose Rifampicin and Levofloxacin for Tuberculous Meningitis Treatment
Author Information
Author(s): Heemskerk Dorothee, Day Jeremy, Chau Tran Thi Hong, Dung Nguyen Huy, Yen Nguyen Thi Bich, Bang Nguyen Duc, Merson Laura, Olliaro Piero, Pouplin Thomas, Caws Maxine, Wolbers Marcel, Farrar Jeremy
Primary Institution: Hospital for Tropical Diseases, Oxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme
Hypothesis
Current antimycobacterial regimes are not potent enough to treat TBM effectively, as most of the antimycobacterial drugs have very low cerebrospinal fluid penetration.
Conclusion
The study aims to improve treatment outcomes for tuberculous meningitis by using higher doses of rifampicin and adding levofloxacin.
Supporting Evidence
- Mortality for untreated tuberculous meningitis is 100%.
- Approximately 25% of HIV-negative and 67% of HIV-positive patients die from tuberculous meningitis.
- Current treatment regimens have poor penetration into the central nervous system.
Takeaway
This study is testing if giving more medicine can help people with a serious brain infection called tuberculous meningitis get better.
Methodology
A randomized, double blind, placebo-controlled trial comparing standard treatment with intensified treatment using high-dose rifampicin and levofloxacin.
Potential Biases
Potential biases in patient selection and treatment adherence may affect the results.
Limitations
The study may not account for all variables affecting treatment outcomes, and results may not be generalizable to all populations.
Participant Demographics
The study will include 750 patients, with a minimum of 350 HIV-positive patients.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website